Abstract Biomedical machine learning (ML) models raise critical concerns about embedded assumptions influencing clinical decision-making, necessitating robust documentation frameworks for datasets that are shared via external repositories. Fairness-aware algorithm effectiveness hinges on users’ prior awareness of specific issues in the data – information such as data collection methodology, provenance and quality.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daniel Bottomly
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia
Keywords targeted therapy cell state monocytic progenitor Introduction In recent years, initial remission rates for elderly patients with acute myeloid leukemia (AML) have seen improvement due to the combination therapy of the BCL2 inhibitor venetoclax (ven) with hypomethylating agents azacitidine (aza) and decitabine.1,2 However, drug resistance and disease relapse continue to be major hurdles in the long-term management and overall survival of patients with AML due to the heterogeneity of...
Utilizing cohort-level and individual networks to predict best response in patients with metastatic triple negative breast cancer - npj Precision Oncology
Abstract Given the highly aggressive and heterogeneous nature of metastatic triple-negative breast cancer, molecular subtypes have been evaluated for their utility in patient stratification and therapeutic selection. Leveraging both our unique longitudinal multimodal analysis of serial tumor biopsies, as well as existing public reference cohorts, we refined clinically relevant molecular subtypes through de-novo network-based approaches.
Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial
ZIM has received institutional grants/research support from AstraZeneca, Eli Lilly, and GSK; and received consulting fees / advisory boards from Gilead, Lilly, Merck, Novartis, AstraZeneca, and Daiichi Sankyo. NL and JA are employees of AstraZeneca and own AstraZeneca stock.
Upregulation of HOXA3 by isoform‐specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia
CONFLICT OF INTEREST STATEMENT No competing interests to disclose. Supporting Information Filename Description bjh19563-sup-0001-Supinfo.zipZip archive, 19.5 MB Appendix S1. REFERENCES 1, , . The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. J Biol Chem. 1993; 268(13): 9172–9175. 2. Wilms' tumour 1 (WT1) in development, homeostasis and disease. Development. 2017; 144(16): 2862–2872. 3, , , , , , et al.
Just how transformative will AI/ML be for immuno-oncology?
Just how transformative will AI/ML be for immuno-oncology? Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
Acknowledgments We thank all of our patients at all sites for donating precious time and tissue. DNA and RNA quality assessments, library creation, and short-read sequencing assays were performed by the OHSU Massively Parallel Sequencing Shared Resource.
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance
Highlights • Stepwise model of early to late gilteritinib resistance recapitulates human disease • Early resistant cells in marrow microenvironment rely on AURKB to resume growth • Pre-existing NRAS mutations expand in late resistance and drive relapse • Metabolic reprogramming occurs during evolution of gilteritinib resistance Summary Our study details the stepwise evolution of gilteritinib resistance in FLT3-mutated acute myeloid leukemia (AML).
CPTAC consortium: Cell Press
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
CPTAC consortium: Cell Press
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
Haijiao Zhang, Beth Wilmot, Daniel Bottomly, Kim-Hien T. Dao, Emily Stevens, Christopher A. Eide, Vishesh Khanna, Angela Rofelty, Samantha Savage, Anna Reister Schultz, Nicola Long, Libbey White, Amy Carlos, Rachel Henson, Chenwei Lin, Robert Searles, Robert H. Collins, Daniel J. DeAngelo, Michael W. Deininger, Tamara Dunn, Than Hein, Marlise R. Luskin, Bruno C. Medeiros, Stephen T. Oh, Daniel A. Pollyea, David P. Steensma, Richard M. Stone, Brian J. Druker, Shannon K. McWeeney, Julia E. Maxson, Jason R.
Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis
Haijiao Zhang, Beth Wilmot, Daniel Bottomly, Kim-Hien T. Dao, Emily Stevens, Christopher A. Eide, Vishesh Khanna, Angela Rofelty, Samantha Savage, Anna Reister-Schultz, Nicola Long, Libbey White, Amy Carlos, Rachel Ann Henson, Chenwei Lin, Robert Searles, Robert H. Collins, Daniel J. DeAngelo, Michael W. Deininger, Tamara Dunn, Hein Than, Marlise R. Luskin, Bruno C. Medeiros, Stephen T. Oh, Daniel A. Pollyea, David P. Steensma, Richard M. Stone, Brian J. Druker, Shannon K. McWeeney, Julia E. Maxson, Jason R.
Functional genomic landscape of acute myeloid leukaemia
Abstract The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. Here we report initial findings from the Beat AML programme on a cohort of 672 tumour specimens collected from 562 patients. We assessed these specimens using whole-exome sequencing, RNA sequencing and analyses of ex vivo drug sensitivity.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Daniel
Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack